Chlorpropamide treatment restores the reduced carrageenan-induced paw edema and pleural exudate volume in diabetic rats.
OBJECTIVE
Knowing that hyperglycemia is a hallmark of vascular dysfunction in diabetes and that neonatal streptozotocin-induced diabetic rats (n-STZ) present reduced inflammatory response, we decided to evaluate the effect of chlorpropamide-lowered blood glucose levels on carrageenan-induced rat paw edema and pleural exudate in n-STZ.


METHODS
Diabetes was induced by STZ injection (160 mg/kg, ip) in neonates (2-day-old) Wistar rats.


METHODS
n-STZ diabetic rats were treated with chlorpropamide (200mg/kg, 15d, by gavage) 8 weeks after STZ injection.


METHODS
Carrageenan-induced paw edema and pleural exudate volumes were assessed concomitantly with peripheral and exudate leukocyte count. We also evaluated the expression of inducible nitric oxide synthase (iNOS) in lungs of all experimental groups.


RESULTS
Chlorpropamide treatment improved glucose tolerance, beta-cell function (assessed by HOMA-beta), corrected paw edema, and pleural exudate volume in n-STZ. Neither leukocyte count nor iNOS expression were affected by diabetes or by chlorpropamide treatment.


CONCLUSIONS
Chlorpropamide treatment by restoring beta-cell function, reducing blood sugar levels, and improving glucose tolerance might be contributing to the correction of the reduced inflammatory response tested as paw edema and pleural exudate in n-STZ diabetic rats.
Sartoretto
J L
JL
Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, AV. Professor Lineu Prestes 1524, Cidade Universitária, CEP 05508-900, São Paulo, SP, Brazil.
Melo
G A
GA
Bersani-Amado
C A
CA
Oliveira
M A
MA
Santos
R A
RA
Passaglia
R T
RT
Nigro
D
D
Cuman
R K N
RK
Carvalho
M H
MH
Fortes
Z B
ZB
D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D002351:Carrageenan; D002747:Chlorpropamide / Q000627:therapeutic use*; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy* / Q000503:physiopathology; D004487:Edema / Q000209:etiology* / Q000503:physiopathology; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D050417:Insulin-Secreting Cells / Q000187:drug effects / Q000502:physiology; D008297:Male; D052247:Nitric Oxide Synthase Type II / Q000235:genetics; D010998:Pleurisy / Q000209:etiology* / Q000503:physiopathology; D012333:RNA, Messenger / Q000032:analysis; D051381:Rats; D017208:Rats, Wistar; D013311:Streptozocin
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D012333:RNA, Messenger; D013311:Streptozocin; D002351:Carrageenan; D052247:Nitric Oxide Synthase Type II; D002747:Chlorpropamide